ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
April 18, 2022 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Antimicrobial Coatings Market Size & Share | North America, Europe, & APAC Industry Forecasts 2026: Graphical Research
February 23, 2022 05:00 ET
|
Graphical Research
Pune, India, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The global antimicrobial coatings market size is projected to show tremendous growth during the forecast timeframe. The COVID-19 pandemic was...
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
May 03, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Corporation Announces Proposed Public Offering of Common Stock
March 17, 2021 16:01 ET
|
ContraFect Corporation
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
July 20, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria
February 21, 2020 08:00 ET
|
Arch Biopartners
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Arch...
Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage
February 13, 2018 08:00 ET
|
Arch Biopartners
TORONTO, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) a portfolio based biotechnology company, announced today the investigator...
Antimicrobial Coatings Market worth $7bn by 2024: Global Market Insights, Inc.
April 10, 2017 07:30 ET
|
Global Market Insights, Inc
Ocean View, Delaware, April 10, 2017 (GLOBE NEWSWIRE) -- The research report “Antimicrobial Coatings Market Size By Product (Antimicrobial Powder Coatings [Silver], Surface Modifications and...
Achaogen Reports First Quarter 2016 Financial Results
May 05, 2016 16:05 ET
|
Achaogen, Inc.
-- Accelerated Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin; Top-Line Data in First Quarter of 2017 and NDA Submission in Second Half of 2017...
German Study Finds Bacteria on Seventy Percent of Dental Bib Holders
March 19, 2012 13:43 ET
|
DUX Dental
OXNARD, Calif., March 19, 2012 (GLOBE NEWSWIRE) -- This week, researchers at the University of Witten/Herdecke in North Rhine-Westphalia, Germany released a clinical study indicating that the...